Prostate cancer is one of the most commonly diagnosed cancers in men, but not every tumor behaves aggressively. Many prostate tumors grow so slowly that they may never cause symptoms or shorten a person’s life, particularly when detected in older adults or in patients with other serious health conditions. Historically, however, a diagnosis could lead quickly to radical prostatectomy, radiation therapy, or other interventions. These treatments can be lifesaving for aggressive disease, but they may also cause long-term complications, including urinary incontinence, erectile dysfunction, bowel problems, and other effects that can significantly alter quality of life. Active surveillance emerged as a way to separate cancers requiring immediate treatment from those that can be safely monitored.

The strategy is not the same as ignoring cancer. Active surveillance generally involves regular testing, including prostate-specific antigen measurements, repeated clinical evaluations, imaging such as magnetic resonance imaging, and, when appropriate, follow-up biopsies. The purpose is to detect biological or pathological signs that a tumor is becoming more dangerous. If evidence of progression appears, treatment can still be offered. Watchful waiting is related but usually less intensive and is often used when the goal is to manage symptoms or overall health rather than to pursue curative treatment. Both approaches reduce the risk that a patient will experience treatment-related harm when the cancer itself poses little immediate danger.

The new study focuses on care delivered throughout the national VA Healthcare System, one of the largest integrated health systems in the United States. Its findings are important because the VA serves a broad veteran population and maintains an extensive clinical infrastructure capable of tracking diagnostic and treatment patterns across many facilities. The reported increase indicates that conservative management is no longer limited to specialized academic centers or individual physicians who have adopted it early. Instead, it has become a much more common part of routine prostate cancer care within the VA, suggesting that system-wide policies, clinical education, improved risk classification, and greater confidence in surveillance may have influenced medical decision-making.

The most striking change occurred among veterans with low-risk prostate cancer. In this group, the proportion managed with active surveillance or watchful waiting rose from just over one in four patients to nearly all patients. A shift from 27% to 93% represents more than a gradual change in clinical preference; it signals a fundamental transformation in the default response to a favorable diagnosis. For many patients, the new approach may mean avoiding surgery or radiation altogether, while retaining the possibility of treatment if their disease later shows evidence of progression. The result could be fewer avoidable complications without sacrificing the opportunity for curative intervention in men whose cancers become more threatening.

The increase was also substantial for favorable intermediate-risk disease, although the final proportion was lower. Use of surveillance or watchful waiting rose from 14% to 61%, meaning that a majority of veterans in this category were managed without immediate definitive treatment. Intermediate-risk disease is more complex because it includes tumors with a greater possibility of progression than low-risk cancers. Some patients may still benefit from treatment at diagnosis, while others may have tumors whose biological behavior remains sufficiently favorable for careful monitoring. The finding that surveillance expanded in this group suggests that clinicians are increasingly incorporating individual tumor characteristics, patient age, life expectancy, preferences, and competing medical conditions into treatment decisions rather than relying on risk labels alone.

The study also highlights why quality matters alongside incidence. Increasing the number of men placed on surveillance is not enough if follow-up is inconsistent or if patients do not receive the testing needed to identify progression. High-quality active surveillance requires reliable systems for scheduling repeat assessments, communicating results, reviewing imaging and pathology, and ensuring that a patient can transition promptly to treatment when necessary. In a large healthcare network, these processes can be difficult to standardize. The researchers’ emphasis on the quality of surveillance indicates that the success of conservative management depends not merely on delaying treatment, but on maintaining an organized clinical safety net around every patient.

Despite the overall improvement, the findings point to continuing disparities in care. The summary of the study indicates that some veterans still do not receive comparable management for favorable-risk prostate cancer, although the available information does not specify which demographic, geographic, socioeconomic, or clinical groups are most affected. Differences may arise from access to urologists, availability of magnetic resonance imaging or confirmatory biopsy, variation among medical centers, health literacy, transportation barriers, or differences in how clinicians and patients understand the risks of surveillance. Addressing such gaps will require more than publishing guidelines. Health systems may need standardized protocols, decision-support tools, patient education, quality audits, and targeted resources for facilities or populations where surveillance is used less consistently or delivered with lower quality.

The results arrive during a broader reassessment of cancer treatment, in which the central question is increasingly not simply whether a tumor can be treated, but whether it needs to be treated immediately. For veterans with favorable-risk prostate cancer, the VA experience suggests that careful monitoring can become the dominant form of care when a health system aligns clinical practice with the biology of the disease. The findings do not mean that surgery and radiation are unnecessary for all prostate cancer patients, nor that surveillance is risk-free. They show instead that a diagnosis can be managed with greater precision, reserving intensive treatment for cancers most likely to benefit from it. By helping many men avoid unnecessary intervention while preserving a pathway to treatment, the VA’s shift may offer a model for improving cancer care beyond the veteran population.

Subject of Research: Prostate cancer management and the use and quality of active surveillance or watchful waiting in the US Department of Veterans Affairs Healthcare System.

Web References: https://doi.org/10.1001/jama.2026.13471

References: Cooperberg MR et al., Research Letter published in JAMA, DOI: 10.1001/jama.2026.13471.

Keywords: Prostate cancer, active surveillance, watchful waiting, Veterans Affairs Healthcare System, low-risk prostate cancer, favorable intermediate-risk prostate cancer, cancer treatment, overtreatment, health disparities.

As prostate cancer predominantly affects middle-aged and elderly men, the lack of unified clinical guidelines poses significant challenges in patient care. The complexity of the disease, especially when distinguishing between localized and metastatic cases, exacerbates the urgency for informed and standardized management practices. Despite various international and domestic guidelines existing, there remains a daunting void in high-level evidence concerning crucial aspects of prostate cancer treatment. This inadequacy has led Chinese experts to unite in a concerted effort to enhance the standard of care, making timely interventions possible to improve health outcomes for patients afflicted by this disease.

The consensus, which was published on October 10, 2024, in the prestigious journal UroPrecision, reflects extensive deliberations and collective input from a panel of elite specialists, including urologists, medical oncologists, and radiologists. These experts addressed 19 pivotal questions focusing on various aspects of prostate cancer management, ranging from screening protocols and biopsy techniques to advanced treatment options for localized, locally advanced, and metastatic disease. The thorough examination of these topics demonstrates the commitment of Chinese professionals to establish a well-defined framework that clinicians can follow to navigate the complexities of prostate cancer effectively.

One of the most significant conclusions drawn from the consensus is the overwhelming support for prostate-specific antigen (PSA) screening, with a noteworthy 89% of the participating experts affirming its efficacy in reducing prostate cancer-specific mortality rates. This statistic serves as a powerful testament to the importance of early detection in combating the disease. The experts recommend initiating PSA screening at the age of 50 for men who do not have a family history of prostate cancer or carry BRCA2 mutations, thereby setting a clear benchmark for preventive healthcare practices.

In the realm of treatment strategies, the consensus advocates for the incorporation of next-generation hormonal agents in combination with androgen deprivation therapy (ADT) for patients diagnosed with high-volume metastatic castration-sensitive prostate cancer. This progressive approach emphasizes the need for advanced treatment modalities that can tackle the aggressive nature of metastatic forms of the disease. For individuals categorized as nonmetastatic castration-resistant prostate cancer patients, about 75% of experts concurred that additional assessments, such as Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT), should be pursued in cases where standard imaging fails to reveal metastasis.

This consensus reflects a significant stride toward the standardization of prostate cancer management in China, as articulated by Nianzeng Xing, the corresponding author of the study. He highlighted that this document serves as a vital reference that offers comprehensive guidance for clinicians, documenting the entire patient journey from screening to final treatment and follow-up. Such a meticulous effort underlines how experts aim to transform the management landscape of prostate cancer, providing a lifeline for patients who are grappling with the complexities of their treatment options.

Furthermore, the consensus document sets forth actionable, evidence-based recommendations engineered to support healthcare professionals in effectively navigating the challenging terrain of prostate cancer management. By highlighting critical challenges and offering a cohesive resolution through expert-driven consensus, there lies potential not only to elevate patient outcomes but also to enhance the quality of life for those battling the disease. These strategic recommendations related to both screening practices and treatment protocols stand poised to make a substantial difference in the clinical practices deployed throughout China.

The rapidly increasing incidence of prostate cancer necessitates a proactive and unified response from the medical community. The consensus created by noted specialists could serve as a vital instrument in fighting against this growing health threat, paving the way for improved care and treatment methodologies that could ultimately reduce the burden of the disease. The forward-thinking initiatives encapsulated in the consensus aim to foster a more structured approach to managing prostate cancer, all while paying careful attention to the nuances of patient care.

As the healthcare system continues to evolve, the implications of this consensus could resonate far beyond just clinical settings. By addressing pressing medical challenges through expert-driven insights, the guidelines foster a culture of collaboration and standardization that could enhance overall health outcomes for patients across China, regardless of geographic or socioeconomic barriers. The collective effort in forging this consensus illustrates a powerful commitment to advancing care standards while ensuring that healthcare professionals are equipped with the knowledge necessary to confront prostate cancer effectively.

In summation, the consensus published in UroPrecision marks a crucial advance in the discourse surrounding prostate cancer management in China. The syntheses of expert opinions and the establishment of a coherent framework signify a turning point in how clinicians will approach diagnosis, treatment, and patient follow-up strategies. The diligence shown by Chinese specialists in crafting this document embodies a proactive commitment to improving patient care and addressing the immediate needs of those affected by prostate cancer, presenting a large step forward in the quest for improved survival rates and health outcomes in the face of an escalating health challenge.

Subject of Research: Prostate Cancer Management
Article Title: Hot Issues on Chinese Expert Consensus of Prostate Cancer Management
News Publication Date: 10-Oct-2024
Web References: UroPrecision
References: DOI 10.1002/uro2.76
Image Credits: Not applicable

Keywords: Prostate cancer, PSA screening, androgen deprivation therapy, metastatic prostate cancer, clinical guidelines.